Revelation Biosciences (REVB) Competitors

Revelation Biosciences (NASDAQ:REVB) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.

Which has more volatility & risk, REVB or AFMD?

Revelation Biosciences has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Affimed has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Which has higher valuation and earnings, REVB or AFMD?

Revelation Biosciences has higher earnings, but lower revenue than Affimed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$120K	-$139.86	-0.02
Affimed	$877K	18.27	-$114.66M	N/A	N/A

Do institutionals and insiders hold more shares of REVB or AFMD?

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 30.8% of Affimed shares are held by institutional investors. 0.1% of Revelation Biosciences shares are held by insiders. Comparatively, 3.8% of Affimed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer REVB or AFMD?

In the previous week, Affimed had 2 more articles in the media than Revelation Biosciences. MarketBeat recorded 5 mentions for Affimed and 3 mentions for Revelation Biosciences. Affimed's average media sentiment score of 0.55 beat Revelation Biosciences' score of 0.31 indicating that Affimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revelation Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Affimed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate REVB or AFMD?

Affimed has a consensus target price of $13.50, suggesting a potential upside of 1,256.78%. Given Affimed's stronger consensus rating and higher probable upside, analysts clearly believe Affimed is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Affimed	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Is REVB or AFMD more profitable?

Revelation Biosciences has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Revelation Biosciences' return on equity of -193.51% beat Affimed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-193.51%	-84.00%
Affimed	-7,836.26%	-193.84%	-107.24%

Does the MarketBeat Community prefer REVB or AFMD?

Affimed received 409 more outperform votes than Revelation Biosciences when rated by MarketBeat users. Likewise, 69.79% of users gave Affimed an outperform vote while only 63.83% of users gave Revelation Biosciences an outperform vote.

Company	Underperform	Outperform
Revelation Biosciences	Outperform Votes 30 63.83%	Underperform Votes 17 36.17%
Affimed	Outperform Votes 439 69.79%	Underperform Votes 190 30.21%

Summary

Affimed beats Revelation Biosciences on 11 of the 15 factors compared between the two stocks.